Evolocumab (Repatha®)

15 hours ago

4 min read

Drug class: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; monoclonal antibody (1)

Mechanism of Action

Evolocumab is a monoclonal antibody that binds to circulating PCSK9 and prevents it from binding to low-density lipoprotein receptors (LDL-R) on hepatocytes. In general, PCSK9 promotes LDL-R degradation after low-density lipoprotein (LDL) is internalized, reducing the number of receptors available to remove LDL from the circulation.

By inhibiting PCSK9, evolocumab prevents LDL-R degradation and allows more receptors to recycle to the hepatocyte surface. The increased availability of LDL-R enhances hepatic clearance of LDL, resulting in a reduction in circulating low-density lipoprotein cholesterol (LDL-C) levels (2).

Approved Indications

Established cardiovascular disease (CVD): Adults, to reduce the risk of myocardial infarction, stroke, and coronary revascularization (1)
Primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH): Adults, to reduce LDL-C (1)
HeFH: Pediatric patients ≥10 years, to reduce LDL-C (1)
Homozygous familial hypercholesterolemia (HoFH): Adults and pediatric patients ≥10 years, to reduce LDL-C (1)

Dosage and Administration

Adults with hypercholesterolemia or at increased CV risk: 140 mg SC q2w or 420 mg SC once monthly (1)
HeFH: 140 mg SC q2w or 420 mg SC once monthly in adults and pediatric patients ≥10 years (1)
HoFH: 420 mg SC once monthly; may increase to 420 mg q2w if a clinically meaningful response is not achieved after 12 weeks (1)
Patients receiving lipid apheresis: May initiate 420 mg SC q2w, administered after the apheresis session (1)
Administration: SC injection into the abdomen, thigh, or upper arm; rotate injection sites with each administration (1)

Key clinical benefits

Helps reduce LDL-C when added to background lipid-lowering therapy (3)
Reduces the risk of major CV events in adults with established atherosclerotic cardiovascular disease (ASCVD) (3)
Provides substantial LDL-C reductions in patients with HeFH and HoFH (1,5)
Maintains sustained LDL-C lowering with continued treatment (3)

Key clinical trials

FOURIER – Evolocumab in ASCVD

This randomized, double-blind, placebo-controlled Phase 3 trial evaluated evolocumab in 27,564 patients with established ASCVD and LDL-C ≥70 mg/dL receiving statin therapy. Patients received evolocumab 140 mg q2w or 420 mg monthly or placebo. At 48 weeks, evolocumab reduced LDL-C by 59% compared with placebo. The primary composite CV endpoint occurred in 9.8% of patients receiving evolocumab versus 11.3% with placebo (HR, 0.85; 95% CI, 0.79–0.92; P<0.001). The key secondary endpoint of CV death, myocardial infarction, or stroke occurred in 5.9% versus 7.4%, respectively (HR, 0.80; 95% CI, 0.73–0.88; P<0.001), demonstrating reduced CV events with evolocumab (3).

RUTHERFORD-2 – Evolocumab in HeFH

This randomized Phase 3 trial evaluated evolocumab in 331 patients with HeFH receiving stable lipid-lowering therapy. Patients received evolocumab 140 mg q2w, 420 mg monthly, or placebo. At Week 12, evolocumab reduced LDL-C by approximately 59.2% with the q2w regimen and 61.3% with the monthly regimen compared with placebo, demonstrating substantial LDL-C lowering in HeFH (4).

DESCARTES – Evolocumab in hyperlipidemia

This Phase 3 trial evaluated evolocumab in 901 patients with hyperlipidemia receiving different background lipid-lowering therapies. At Week 52, evolocumab 420 mg monthly produced a 57% reduction in LDL-C versus placebo. LDL-C reductions were consistent across treatment groups, including 55.7% with diet alone, 61.6% with atorvastatin 10 mg, 56.8% with atorvastatin 80 mg, and 48.5% with atorvastatin 80 mg plus ezetimibe 10 mg (P<0.001 for all comparisons). The results demonstrated sustained LDL-C lowering regardless of background therapy (5).

Common Adverse Events

Nasopharyngitis (1)
Upper respiratory tract infection (1)
Influenza (1)
Back pain (1)
Injection-site reactions (1)
Diabetes mellitus in patients with established CV disease (1)

Contraindications / Precautions

History of serious hypersensitivity reaction to evolocumab (1)
Discontinue if severe hypersensitivity reactions occur (1)
Monitor for signs and symptoms of hypersensitivity following administration (1)

Special Notes for Clinician

Use evolocumab as an adjunct to diet and appropriate LDL-C-lowering therapy when indicated (1)
Assess LDL-C when clinically appropriate; the LDL-C-lowering effect may be measured as early as 4 weeks after initiation (1)
For the 420 mg monthly regimen, LDL-C may vary during the dosing interval; measurement immediately before the next scheduled dose is recommended when monitoring is required (1)
Rotate SC injection sites between the abdomen, thigh, and upper arm (1)
Train patients or caregivers in proper SC administration and allow refrigerated product to reach room temperature for at least 30 minutes before administration (1)

Abbreviations

ASCVD: atherosclerotic cardiovascular disease; CI: confidence interval; CV: cardiovascular; HeFH: heterozygous familial hypercholesterolemia; HoFH: homozygous familial hypercholesterolemia; HR: hazard ratio; LDL-C: low-density lipoprotein cholesterol; LDL-R: low density lipoprotein receptor; PCSK9: proprotein convertase subtilisin/kexin type 9; q2w: every 2 weeks; SC: subcutaneous.

References

U.S. Food and Drug Administration. REPATHA® (evolocumab) Prescribing Information. Revised July 2026. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125522s049lbl.pdf?utm_source=chatgpt.com
Kasichayanula S, Grover A, Emery MG, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018;57(7):769-779.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
Raal FJ, Kallend D, Ray KK, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2). Lancet. 2015;385:331–340.
Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia (DESCARTES). N Engl J Med. 2014;370:1809–1819.

About the Author

Dr. Lokesh Naik, is a Pharm D graduate with a passion for medical research and medical writing. He has keen interest in understanding pharmacological agents, their efficacy and safety, and their benefits to patients. His current focus is on lifestyle disorders including diabetes.

Click on this link to connect with the author.

Disclaimer

The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in